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Janus kinases (JAKs) are key effectors in controlling
immune responses and maintaining hematopoiesis.
SOCS3 (suppressor of cytokine signaling-3) is a
major regulator of JAK signaling and here we investi-
gate the molecular basis of its mechanism of action.
We found that SOCS3 bound and directly inhibited
the catalytic domains of JAK1, JAK2, and TYK2
but not JAK3 via an evolutionarily conserved motif
unique to JAKs. Mutation of this motif led to the
formation of an active kinase that could not be
inhibited by SOCS3. Surprisingly, we found that
SOCS3 simultaneously bound JAK and the cytokine
receptor to which it is attached, revealing how spec-
ificity is generated in SOCS action and explaining
why SOCS3 inhibits only a subset of cytokines.
Importantly, SOCS3 inhibited JAKs via a noncompet-
itive mechanism, making it a template for the devel-
opment of specific and effective inhibitors to treat
JAK-based immune and proliferative diseases.
INTRODUCTION
Both hematopoiesis and the immune response are regulated
by the action of cytokines through activation of the Janus
kinase-signal transducer and activator of transcription-sup-
pressor of cytokine signaling (JAK-STAT-SOCS) signal trans-
duction pathway (O’Shea and Murray, 2008).
There are four mammalian JAKs (JAK1-3 and TYK2), each
consisting of four domains (Figure S1 available online; Wilks
and Harpur, 1994). The N-terminal FERM domain binds constitu-
tively to the appropriate membrane-bound receptor whereas the
C-terminal kinase (catalytic) domain phosphorylates substrate
proteins. Between these are a noncanonical SH2 domain and
a pseudokinase domain, the most distinctive feature of the
JAK family. This domain has recently been shown to be catalyt-
ically active (Ungureanu et al., 2011) and it regulates the activity
of the JH1 domain (Saharinen et al., 2000).Genetic deletion of each individual JAK leads to various
immunological and hematopoietic defects; however, aberrant
activation of JAKs can be likewise pathological. Threemyelopro-
liferative disorders (polycythemia vera, essential thrombocythe-
mia, and primary myelofibrosis) are caused by a single point
mutation in JAK2 (JAK2V617F) (James et al., 2005; Levine et al.,
2005) that renders the kinase constitutively active and results
in cytokine-independent activation of JAK-based signaling path-
ways. An even more severe phenotype results from activation of
JAK by oncogenic fusion, for example TEL-JAK2, which has
been studied because of its role in childhood T and B cell acute
lymphoblastic leukemia (Lacronique et al., 2000).
In order to prevent aberrant proliferation, JAK activity is regu-
lated in a number of ways. The primary negative regulators of the
JAKs are a family of proteins known as the suppressors of cyto-
kine signaling (SOCS) (Endo et al., 1997; Hilton et al., 1998; Naka
et al., 1997; Starr et al., 1997) whose expression is induced by
JAK-STAT activation and they then inhibit the signaling cascade,
creating a negative feedback loop.
All eight SOCS proteins (SOCS1-7 and CIS) contain a central
SH2 domain and a C-terminal SOCS box domain (Hilton et al.,
1998), which interacts with elongins B and C and Cullin5 to cata-
lyze the ubiquitination of bound signaling proteins (Babon et al.,
2009; Kamizono et al., 2001; Zhang et al., 1999). Elegant studies
performed by Yoshimura and colleagues (Sasaki et al., 1999;
Yasukawa et al., 1999) showed that the two most potent
suppressors of signaling, SOCS1 and SOCS3, contain a short
motif, upstream of their SH2 domain, known as the KIR (kinase
inhibitory region), which allows them to suppress signaling by
direct inhibition of JAK catalytic activity. This is their dominant
mode of action in vivo (Boyle et al., 2007; Zhang et al., 2001).
Initial characterization of the KIR noted its amino acid sequence
similarity to the activation loop of JAKs (Sasaki et al., 1999;
Yasukawa et al., 1999). Like most tyrosine kinases, JAKs contain
an activation loop that blocks the catalytic cleft. Autophosphor-
ylation of this loop causes its translocation away from the cata-
lytic site and allows substrate access, thus activating the kinase.
Consequently, it was proposed that the SH2 domain of SOCS1
and SOCS3 binds the activation loop tyrosine phosphate and
the KIR acts as a pseudosubstrate to block the active site (Sasaki
et al., 1999; Yasukawa et al., 1999).Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc. 239
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Mechanism of Inhibition of Janus Kinase by SOCS3Despite the ability of SOCS proteins to bind to and inhibit
JAKs, deletion of individual SOCS genes in mice has revealed
an exquisite specificity for particular cytokine-receptor combina-
tions rather than specific JAKs. For example, SOCS1 inhibits
interferon g signaling without affecting IL-6 signaling whereas
the converse is true for SOCS3 (Alexander et al., 1999; Croker
et al., 2003), yet both cytokine receptor systems utilize the
same JAKs (JAK1 and JAK2) (Murray, 2007). Moreover, the
binding affinities of the SOCS3 SH2 domain for phosphorylated
JAK peptides is several logs lower than that for certain cytokine
receptor phosphopeptides, and this binding is important in intact
cells (Nicholson et al., 2000).
In this study we dissect both the mechanism and specificity of
JAK inhibition by SOCS3 by using biochemical, structural, and
kinetic methods and resolve these apparent discrepancies.
We show that SOCS3 directly inhibits JAK1, JAK2, and TYK2
but not JAK3 because of the presence of a conserved three-
residue motif on the former three JAK family members. By
utilizing two distinct binding surfaces, SOCS3 is able to bind to
JAK and the cytokine receptor to which it is attached simulta-
neously, explaining why SOCS3 is specific for cytokines that
signal through particular receptors. Intriguingly, inhibition occurs
via a mechanism in which SOCS3 does not compete with either
ATP or substrate. This makes SOCS3 a noncompetitive tyrosine
kinase inhibitor and a new template for the future development
of a class of small-molecule JAK inhibitors with distinct advan-
tages over the current ATP analogs used to treat JAK-based
diseases.
RESULTS
SOCS3 Inhibits Substrate Phosphorylation by theKinase
Domain of JAK2
To examine SOCS3 inhibition of JAK kinase activity, we devel-
oped an in vitro kinase assay consisting of three purified,
recombinant components: enzyme (JAK2 catalytic domain,
JAK2JH1), substrate (gp130 cytoplasmic domain, gp130cyt),
and inhibitor (SOCS3). Various chimeras of SOCS3 were also
produced that had the key residues in the KIR, L22-S29,
replaced by the corresponding residues of SOCS1, SOCS4,
or SOCS5 (these are designated SOCS1-3, SOCS4-3, and
SOCS5-3; see Figure S1A). All SOCS proteins were expressed
and purified in complex with elongins B andC, their physiological
SOCS box ligands, because they provide increased stability
and solubility. JAK2JH1 was purified from insect cells. Both
SOCS3 and SOCS1-3 inhibited substrate phosphorylation in
this system (Figure 1A). Inhibition was not substrate specific as
shown by the fact that the use of a different substrate (the acti-
vation loop of JAK2 fused to GST, termed GST-J; Figure 1B)
led to identical results. In contrast, SOCS2, SOCS4, SOCS4-3,
and SOCS5-3 had no effect on phosphorylation of any substrate
tested.
As seen in Figure 1, all SOCS constructs were themselves
phosphorylated to some extent in these assays, as was elon-
ginC. This was not unexpected because the isolated kinase
domain of JAK2, like that of many tyrosine kinases, shows little
substrate specificity and will phosphorylate any tyrosines that
are solvent exposed and not part of ordered secondary struc-
ture. For example, we found a synthetic polymer, poly-Glu4Tyr,240 Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc.to be a good substrate for JAK2JH1 phosphorylation. To verify
that phosphorylation of SOCS3 was not by itself the cause of
decreased gp130cyt phosphorylation, the entire reaction was
spotted onto nitrocellulose membranes, allowing total phos-
phorylation of all components to be quantified. SOCS3 had
a clearly titratable inhibitory effect on JAK-catalyzed phosphor-
ylation with an IC50 of 1 mM (Figure 1C).
A limiting feature of these assays was that the concentration of
SOCS3 required to inhibit JAK2JH1 was similar to the concentra-
tion of substrate. To ensure that it was not a SOCS3-substrate
interaction that was responsible for inhibiting the phosphoryla-
tion reaction, we adopted amore robust enzyme-inhibition assay
format where [Substrate] > > [Inhibitor] > > [Enzyme]. These
assays used high concentrations of a peptide substrate, resi-
dues 693–708 of STAT5b (Saharinen et al., 2003; Zhao et al.,
2010). SOCS3 inhibited phosphorylation of this peptide
substrate with the same IC50 of1 mM (Figure 1D). These results
indicate that SOCS3 functions by blocking the ability of JAK2 to
phosphorylate protein substrates and is therefore a direct inhib-
itor of its catalytic activity.
A SOCS1-SOCS3 Chimera Is a More Potent Inhibitor
than SOCS3
Replacing the KIR of SOCS3 with the corresponding region from
SOCS1 resulted in a chimeric construct (termed SOCS1-3) that
inhibited JAK2 kinase activity with higher affinity than did wild-
type SOCS3 (IC50 values of 0.15 ± .02 and 1.2 ± 0.1 mM, respec-
tively; see Figure 1D), despite there being a difference of only
four residues. A truncated construct of SOCS3, SOCS322-185,
that lacks the SOCS box and hence elonginB and C binding,
was equally effective at inhibiting JAK2. These results show
that the kinase inhibitory activity of SOCS3 relies solely upon
its KIR and extended SH2 domain and not its SOCS box domain.
In addition, the KIR from SOCS1, but not SOCS4 or SOCS5, can
act as a functional replacement, making it likely that SOCS1 acts
in a similar manner to SOCS3.
Both theKIR andSH2Domain of SOCS3AreRequired for
Kinase Inhibition but Phosphotyrosine Binding Is Not
Previous work had highlighted the importance of F25A within the
KIR and R71 within the SH2 domain for SOCS3 function (Nichol-
son et al., 1999; Sasaki et al., 1999). Here we confirm in vitro that
deletion of the first eight residues in the KIR (residues 22–29) or
mutagenesis of F25 and R71 completely abrogated inhibition
(Figure 1E). The KIR in isolation, as a synthetic peptide, could
not inhibit JAK2, even at concentrations 1003 the IC50 values
of the full-length protein (data not shown). The requirement for
R71, which directly binds pTyr, implies that SOCS3 may bind
the phosphorylated activation loop of JAK2 as part of its inhibi-
tory mechanism. However, the addition of a known high-affinity
ligand (KD = 100 nM) for the SOCS3 SH2 domain, murine
gp130750-764 (STASTVEpYSTVVHSG) (Nicholson et al., 2000),
at a 5-fold molar excess had no effect on JAK inhibition by
SOCS3. In addition we were able to form a ternary complex of
JAK2JH1:SOCS3:gp130750-764 containing all three components
at a stoichiometric ratio as analyzed by gel filtration and rpHPLC
(Figure S1). Therefore, although R71 may contact JAK2 when
bound, these results indicate that phosphopeptide binding by
SOCS3 is undisturbed in the presence of JAK2.
Figure 1. SOCS3 and SOCS1-3 inhibit substrate phosphorylation by JAK2
(A) Autoradiography (top) and Coomassie-stained (bottom) SDS-PAGE analysis of JAK2JH1 catalyzed phosphorylation of the gp130 cytoplasmic domain in the
presence of serial 10-fold dilutions of SOCS-elonginBC complexes. Both SOCS3 and a SOCS1-3 chimera were effective inhibitors of substrate phosphorylation.
Gradient bars represent decreasing concentration of each SOCS construct (10 mM, 1 mM, 100 nM, 10 nM, left to right).
(B) As in (A) except a different substrate (GST-J) was used. SOCS concentration was 5 mM, 1 mM, 200 nM, left to right in each case.
(C) Quantitative kinase inhibition experiments. As in (A) except reactions were spotted onto nitrocellulose filters. The experiment was performed in quadruplicate,
raw data shown above and quantitated below. The control reaction (0 SOCS) was normalized to 100%.
(D) SOCS1-3 is a more effective inhibitor of JAK2 than SOCS3. As in (C) except a STAT5b peptide was used as substrate and the reaction spotted onto P81
phosphocellulose paper. Reactions contained 30, 12, 5, 2, 0.8, 0.3, 0.1, 0.04, 0.02, 0.008, 0 mM SOCS (left to right).
(E) SOCS3 constructs that contained mutations in the KIR (F25A), SH2 domain (R71K), or that lacked the first eight residues of the KIR (D22-29) did not inhibit
JAK2. As in (D). Reactions contained 10, 5, 2.5, 1.2, 0.6, 0.3, 0.15, 0 mM SOCS (left to right). The addition of gp130 phosphopeptide (pY) did not affect inhibition.
Error bars represent ± range of two experiments. Data are normalized to no-inhibitor controls.
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Mechanism of Inhibition of Janus Kinase by SOCS3SOCS3 Inhibits JAK1, JAK2, and TYK2 but Not JAK3
because of the Presence of a Three-Residue Motif
in the JAK Insertion Loop
We cloned, expressed, and purified the kinase domains of all
four JAKs and examined the ability of SOCS3 to inhibit them.
SOCS3 inhibited JAK1, JAK2, and TYK2 with IC50 values of
2 mM, 1.5 mM, and 7 mM, respectively, but had no inhibitory effect
on JAK3 (Figure 2A).
A comparison of the sequence of all four kinase domains high-
lighted a number of residues that were conserved within JAK1,
JAK2, and TYK2 but not JAK3. Therefore, a series of mutant
JAK2 molecules were produced that replaced wild-type resi-
due(s) with the corresponding residues from JAK3. All mutant
kinases were catalytically active with no significant differencein specific activity. The only mutations to affect SOCS3-medi-
ated inhibition were in a three-residue motif 1071-1073GQM (Fig-
ure 2B). Mutating this sequence completely abolished the ability
of SOCS3 to inhibit JAK2. Depending on the method of
sequence/structure alignment, these three residues correspond
to either 1043-1045DVP or 1044-1046VPA in JAK3. Both GQM-DVP
and GQM-VPA mutants of JAK2 were insensitive to SOCS3.
The GQMmotif forms the final three residues of the JAK inser-
tion loop (residues 1052–1073; Figure 2D), an insertion that is
specific to JAKs (Haan et al., 2009; Lucet et al., 2006). More
detailed mutagenesis showed that the first and third of these
residues, G1071 and M1073, were absolutely required for
SOCS3 inhibition, whereas mutation of the central glutamine,
Q1072, had only a minor effect (Figure 2C). Mutation of I1074Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc. 241
Figure 2. SOCS3 Inhibits JAK1, JAK2, and TYK2 but Not JAK3 because of a Three-Residue Motif in the JAK Insertion Loop
(A) Kinase inhibition assays were performed with the kinase domain of all four JAKs. Only JAK3JH1 was not inhibited by SOCS3. Error bars represent ± range from
two experiments. Data were normalized to no-inhibitor controls.
(B) Mutating the GQM motif makes JAK2 nonresponsive to SOCS3. All other mutations have no effect.
(C) G1071 and M1073 are absolutely required for SOCS3 inhibition. As in (A) except point mutants of JAK2 were tested.
(D) Sequence alignment of the GQM region of all JAKs and the KIR of SOCS3 and SOCS1. Highly conserved residues are shown boxed in gray, the GQMmotif in
yellow, conserved residues in the KIR in black.
(E) The structure of JAK2 (PDB ID 2B7A). The GQMmotif is solvent exposed and shown in yellow. The locations of mutated residues from (B) are indicated by gray
arrows. *Zebrafish JAK2b is grouped with TYK2 in this figure.
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Mechanism of Inhibition of Janus Kinase by SOCS3also had a small effect on the IC50 of SOCS3. The GQM motif is
solvent exposed (Figure 2E) as expected if it forms a direct
contact with SOCS3. Although the GQM sequence is unlikely
to represent the entire binding surface on JAK, these data indi-
cate that it is an essential motif that allows JAK to be inhibited
by SOCS3.
TheGQMMotif of JAK1, JAK2, and TYK2 Is Conserved in
All Organisms that Contain a SOCS1 or SOCS3 Homolog
All organisms from insects to mammals contain at least one JAK
with vertebrates typically containing four JAKs. A sequence
alignment of JAKs from within these organisms (Figure 2D)
showed that the GQM motif is conserved in JAK1, JAK2, and
TYK2 from all vertebrate species listed with the exception of
zebrafish JAK2b, which contains a highly similar motif (GQT) at242 Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc.this position. Equally, none of these organisms contained this
motif in JAK3 and the corresponding sequence within this region
was not conserved. A sequence comparison of SOCS mirrors
this phenomenon. Only vertebrates have SOCS1 and SOCS3
homologs, and these all have highly similar kinase inhibitory
regions. In contrast, insects contain only SOCS4-7 homologs.
In summary, this analysis shows that all organisms that contain
an expanded JAK system also encode a SOCS protein with
a functional KIR.
Mutating theGQMMotif in JAK1Leads to Prolonged IL-6
Signaling in Live Cells
To examine our hypotheses regarding the specificity of SOCS3
action in a physiological setting, we wished to mutate full-length
JAK to a form that is impervious to inhibition by SOCS3 and to
Figure 3. IL-6-Induced Phosphorylation of STAT3 Is Prolonged in the Presence of JAK1GQM-DVP
(A) Kinase inhibition assays were performed with the kinase domain of JAK1 and JAK1GQM-DVP. JAK1GQM-DVP was not inhibited by SOCS3. Error bars represent ±
range from two experiments. Data were normalized to no-inhibitor controls.
(B) Wild-type and mutant (GQM-DVP) JAK1 constructs were transfected into JAK1/ (U4A) cells. Cells were stimulated with IL-6 plus s-IL-6Ra for 15 min and
then harvested at the indicated times. Lysates were analyzed by immunoblotting with antibodies specific for phosphorylated STAT3, total STAT3, SOCS3,
and JAK1.
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Mechanism of Inhibition of Janus Kinase by SOCS3examine the effect this has on IL-6 signaling. Because JAK2 is
dispensible for IL-6 signaling but JAK1 is not (Murray, 2007),
we cloned and expressed JAK1GQM-DVP which we predicted,
based on our JAK2 experiments, would be resistant to SOCS
inhibition. As shown in Figure 3A, the kinase domain of JAK1 is
active in the presence of the GQM-DVP mutation but it cannot
be inhibited by SOCS3. We then cloned full-length JAK1WT and
JAK1GQM-DVP and transfected these constructs into JAK1/
human fibrosarcoma (U4A) cells (Guschin et al., 1995). These
cells express the gp130 shared coreceptor and hence can be
stimulated with a mixture of IL-6 and soluble IL-6Ra (Guschin
et al., 1995). As shown in Figure 3B, JAK1GQM-DVP was able to
activate STAT3 after IL-6 stimulation, but this activation was pro-
longed compared to wild-type JAK. pSTAT3 was still detectable
4 hr poststimulation in the presence of the DGQM mutants
compared to only 2 hr in the presence of WT JAK. These results
are identical to those seen in Socs3/ cells, which also show
a 2-fold increase in the persistence of pSTAT3 upon IL-6 stimu-
lation (Croker et al., 2003, 2004), and indicate that SOCS3 inhibi-
tion has been completely disrupted in these cells. Collectively,
these data demonstrate that the GQM motif is essential for
SOCS3 inhibition of JAK, both in vitro and in live cells.
NMR Analysis Reveals that SOCS3 Can Interact
with JAK2 and Cytokine Receptor Simultaneously,
via Two Adjacent Binding Surfaces
By using NMR, we mapped the surface of SOCS3 that binds to
JAK2 by chemical shift perturbation. Both 1H-15N-HMQC and
1H-13C-HMQC spectra were recorded with 250 mM labeled
SOCS322-185 ± 500 mM unlabeled JAK2JH1. The gp130 peptide
was present in all experiments because it leads to increased
solubility of SOCS3 but does not interfere with JAK inhibition
(Figure 1).
The 15N-HMQC spectrum of SOCS3 was well dispersed with
narrow line-widths, but the addition of a 2-fold molar excess of
unlabelled JAK2 led to intense line broadening and widespread
chemical shift perturbation (Figure 4B), consistent with the
formation of a 52 kDa SOCS3-JAK2 complex. No line broad-
ening or peak shifts were seen upon addition of JAK2GQM-DVP,which is not susceptible to SOCS inhibition (Figure S2A). Like-
wise, SOCS329-185, which lacks the KIR, showed no interaction
with wild-type JAK2 (Figure S2B). The SOCS3-JAK2 complex
was in slow exchange and hence could not be assigned, but
the surface of SOCS3 that interacts with JAK2 could be mapped
by identifying resonances from the SOCS3 spectra that shifted
when in complex with JAK2. In order to avoid false positives,
only nonoverlapped peaks that shifted by more than one peak
width (0.1 and 0.6 ppm in the 1H and 15N dimensions, respec-
tively) were considered in this analysis. A number of residues,
including K22-S29 (the first eight residues of the KIR), had to
be excluded from analysis on this basis (they are unstructured
in the absence of JAK2 and hence their resonances reside in
a heavily overlapped region of the spectrum). Nevertheless, 21
backbone and 2 side chain amides were identified that shifted
in the presence of JAK2. Several of these shifts were large, for
example S74 had a chemical shift perturbation of >dAV = 0.67
(dAV = (Dd1H
2 + (Dd15N/5)
2/2)1/2). Repeating this analysis on the
methyl region of 1H-13C-HMQC spectra identified a further ten
residues whose methyl groups shifted in the presence of JAK2.
The combination of these data mapped a 30 residue binding
surface on SOCS3 (Table S2). This surface is centered on the
extended SH2 subdomain (ESS) helix (Figure 4) and includes
its junction with the SH2 domain proper, the N-terminal portion
of helix aA, the BC loop, and the DE loop.
Of the ten methyl-containing residues identified, six are within
the ESS helix and five of these have solvent-exposed side chains
in the unbound state, making it likely that they represent part of
the true binding surface. The other residue, L41, forms the junc-
tion with the SH2 domain and appears to anchor the ESS helix to
the core of the SH2 domain by a number of hydrophobic interac-
tions. This residue contains themost upfield shifted resonance in
the SOCS3 spectra (d-CH30.4 ppm) resulting from ring current
effects from Y47, F80, and F102. This shifted even further upfield
in the presence of JAK2, suggesting that a subtle conformation
change in this region moves the Leu side chain closer to one of
these three aromatic groups.
The mapped interaction surface is adjacent to one end of the
pTyr binding groove. Residues that shift upon JAK bindingImmunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc. 243
Figure 4. NMR Analysis Identifies the Surface of SOCS3 that Interacts with JAK2
(A) Ribbon diagram of the structure of SOCS322-185 (PDB ID 2HMH) with important secondary structural motifs indicated. The dashed line indicates the first seven
residues of the KIR, which are unstructured in the absence of JAK.
(B) 1H-15N and 1H-13CHMQC analysis of the SOCS3-JAK2JH1 interaction are shown in upper and lower panels, respectively. The SOCS spectra are in red and the
SOCS3-JAK2JH1 spectrum in black.
(C) Surface diagram of SOCS3. Residues whose resonances shift in the presence of JAK2JH1 highlighted in red. The orientation of SOCS3 on the left is identical to
that in (A).
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Mechanism of Inhibition of Janus Kinase by SOCS3include several (T52-G54) around the pY-2 pocket as well as
several in the BC loop (R71-D75), including R71, which forms
a salt bridge with pTyr. However, residues that display charac-
teristic chemical shift perturbations when the gp130 peptide is
bound (T89, D107, R94, L178) (Babon et al., 2006) maintain these
characteristic chemical shift positions in the presence of JAK2.
In addition, it is clear from chromatographic analysis that the244 Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc.gp130 phosphopeptide remains bound in the presence of
JAK2 (Figure S1).
Taken together, these results indicate that the JAK2 binding
surface on SOCS3 borders but does not overlap the phosphotyr-
osine binding groove. This surface can be defined as consisting
of the KIR, ESS helix, and the edge of the pTyr binding groove. By
binding JAK and specific cytokine receptors (which are already
Immunity
Mechanism of Inhibition of Janus Kinase by SOCS3associated with JAK) simultaneously, SOCS3 becomes part of
a high-affinity ternary complex. A model in which this ternary
complex underpins the specificity of SOCS3 (Figure S2) will be
discussed.
SOCS3 Is a Noncompetitive Inhibitor of JAK2
The model for the mechanism of JAK inhibition by SOCS3 has
been that the KIR acts as a pseudosubstrate and thereby blocks
access to the active site (Yasukawa et al., 1999). Kinases have
two substrates: ATP (the phosphate donor) and a tyrosine-con-
taining substrate (the phosphate acceptor). If SOCS3 acts as
a pseudosubstrate, then this implies that it will compete with
the binding of one or both of these substrates. This can be
addressed by performing steady-state enzyme kinetics in the
presence of SOCS3 (Cornish-Bowden, 2004).
Kinetic experiments were performed at 25C, with an enzy-
me:substrate ratio > 1:1000 (10 nM enzyme:0.01–5 mM STAT
peptide). Under these conditions, product formation was linear
with time for >45 min, although two time points (7.5 and
15 min) were taken in all experiments to ensure that this was
the case. Results were quantified with scintillation counting
and phosphorimaging. When the ATP concentration was varied
(0–1 mM), the STAT substrate concentration was fixed at
1.6 mM. Conversely, when the STAT peptide concentration was
varied (0–2.5 mM), the ATP concentration was fixed at 2 mM.
JAK2JH1 had KM
ATP = 140 mM and KM
peptide = 0.6 mM under
these conditions. Initial reaction velocity was plotted against
substrate concentration at various concentrations of inhibitor
(Figure 5).
Surprisingly, these analyses showed that SOCS3 is a
noncompetitive inhibitor of JAK2JH1, with respect to both ATP
and substrate. This was apparent by linear least-squares fitting
of the data to a mixed inhibition model with Sigmaplot as well
as by Lineweaver-Burk reciprocal analyses (Figure 5, lower
panels). Lines that intersect on the abscissa indicate noncom-
petitive inhibition. Dixon plot analyses (Dixon, 1953) of these
data are shown in Figure S3A. These analyses were performed
on three separate occasions, each time in duplicate with
different preparations of both enzyme and inhibitor. Fitting of
the data yielded Ki = 1.5 ± 0.7 mM and 1.2 ± 0.3 mM versus
substrate and ATP, respectively. These results can be con-
trasted both qualitatively and quantitatively to identical experi-
ments performed with ADP as inhibitor (Figure S3B), which
gives rise to the expected ATP-competitive inhibition curves.
One attribute of noncompetitive inhibition is that the IC50 is not
affected by substrate concentration. As shown in Figure 5,
SOCS3 inhibited JAK with identical IC50 values at ATP and
substrate concentrations that varied by 40-fold. In contrast,
the IC50 of the ATP-competitive inhibitors ADP and CMP-6
increased in the presence of high ATP concentration, but not in
the presence of high substrate concentration, as expected.
Collectively, these results show that SOCS3 is a noncompetitive
inhibitor of JAK2 and therefore imply that it does not act by
blocking the active site of the kinase.
Mechanism of SOCS3-Mediated Suppression
of JAK/STAT Signaling
In considering the molecular mechanism of SOCS inhibition of
JAK, we thought it most likely that SOCS3 was directly inhibitingphosphate transfer. Many kinases have the ability to catalyze the
transfer of a phosphate moiety to a water molecule, rather than
to tyrosine, thereby acting as an ATPase. We reasoned that if
the mode of action of SOCS3 is to inhibit phosphate transfer,
then it should also inhibit phosphate transfer to water and hence
the ability of JAK2 to act as an ATPase. Therefore, we measured
the ATPase activity of JAK2JH1 in the presence and absence of
SOCS3.
As shown in Figure 6, we unexpectedly observed a small, but
reproducible, activation of JAK2 ATPase activity in the presence
of SOCS3. SOCS3 and SOCS1-3 stimulated the ATPase activity
of JAK2 by nearly 2-fold. SOCS3F25A had no effect. This activity
titrated with an apparent EC50 of 2 mM. These results indicate
that SOCS3 specifically inhibits the ability of JAK to transfer
phosphate to tyrosine but does not inhibit its ability to hydrolyze
ATP and transfer phosphate to water. Our favored molecular
model of inhibition, incorporating this information, will be
discussed.
Because the rate-limiting step of a number of kinases is
product (ADP) release (Adams, 2001), we wished to rule out
the possibility that SOCS3 may act by stabilizing a JAK-ADP
(Enzyme-Product) complex. Such a mechanism implies that
JAK would be insensitive to the presence of SOCS3 during the
first round of catalysis, when ADP is absent. However, single
turnover experiments showed that SOCS3 was still a potent
inhibitor of JAK under these conditions (Figure S4A). In addition,
we did not observe any synergistic effect when a combination of
SOCS3 and ADP were used in standard kinase inhibition exper-
iments (Figure S4B).
Collectively, these results show that ATP is still hydrolyzed by
JAK in the presence of SOCS3 and thereby confirm that SOCS3
does not compete with ATP for binding. Therefore, inhibition of
JAK by SOCS3 will not be affected by a high intracellular ATP
concentration.
DISCUSSION
The prevailing model of SOCS3 action has been that it is
recruited to specific cytokine receptors by its SH2 domain and
once there would eventually engage JAK with both its SH2
domain and KIR. The SH2 domain would bind the phosphory-
lated activation loop of JAK and the KIR would then block ATP
binding (Sasaki et al., 1999). We now show that SOCS3 interacts
with both JAK and the gp130 receptor simultaneously by utilizing
two adjacent binding surfaces and that ATP binding by JAK is
unaffected. Such a mode of action explains the specificity of
SOCS3 and has important consequences both biologically and
therapeutically on a number of fronts as now discussed.
First, the ability of SOCS3 to bind to JAK and simultaneously to
the receptor to which it is attached leads to an unusual ternary
complex in which each moiety is directly bound to the other
two. For such a ternary complex to dissociate, at least two direct
interactions must be broken, and consequently the overall
affinity of such a complex is higher than any of the individual
associations. It follows, therefore, that cytokines that utilize
receptors with SOCS3 binding sites (e.g., IL-6) will be effectively
inhibited by SOCS3 (Wormald et al., 2006), whereas cytokines
that signal through receptors that lack such a site (e.g., IFN-g)
will not, even though they may signal through the same JAKs.Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc. 245
Figure 5. SOCS3 Is a Noncompetitive Inhibitor of JAK2
(A) Michaelis-Menten (top) and Lineweaver-Burk (bottom) analysis of SOCS3 inhibition of JAK2JH1. ATP (left) and peptide substrate (right) titrations show
that SOCS3 alters Vmax but not Km, indicating noncompetitive inhibition. Inhibition experiments were performed with 10 nM JAK and 0, 0.5, 1, 2, 4, 8 mM SOCS3
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Figure 6. SOCS3 Has an Activating Effect on JAK2JH1 ATPase
Activity
(A) JAK-catalysed ATPase assays were performed in the presence of various
concentrations of SOCS3/elonginBC constructs, analyzed by thin-layer
chromotagraphy, and quantified. SOCS3 and SOCS1-3 enhanced the ATPase
activity of JAK2 but the KIR mutant (F25A) did not.
(B) Raw data used to generate the EC50 curves shown in (A). JAK2JH1
hydrolyzed ATP at 0.05 s1 under these conditions compared to 0.09 s1 in the
presence of 15 mM SOCS3. Error bars represent ± range, two experiments.
Data are normalized to no-inhibitor controls.
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JAK2, and TYK2 in the absence of receptor, it does so with rela-
tively poor (micromolar) affinity. Therefore, when artificially over-
expressed, SOCS3 can be predicted to inhibit signaling via any
cytokine that utilizes JAK1, JAK2, or TYK2, but when present
at physiological levels, SOCS3 will inhibit only cytokines that
signal through particular receptors. This has been seen in
numerous studies and explains why SOCS3 shows detectable,
but greatly impaired, inhibition of JAK-STAT signaling through(top to bottom curves, respectively, in upper panels) with varying concentrations
indicate noncompetitive inhibition. Error bars represent ± range from two experim
(B) JAK2 inhibition experiments were performed in the presence of SOCS3 (top, t
ADP and CMP-6 (bottom). The IC50 values of SOCS3 were unaffected by ATP c
range from two experiments. Data are normalized to no-inhibitor controls.gp130Y757F compared to wild-type gp130 (Jenkins et al., 2005;
Nicholson et al., 2000). Likewise, it has been shown that IFN-g
signaling is only poorly suppressed by SOCS1 when its binding
site on the IFN-g receptor (pTyr441) has been mutated (Starr
et al., 2009), and we suggest that SOCS1 and SOCS3 both share
this mechanism of receptor dependence to gain high specificity
and efficacy toward particular cytokines.
Even in the absence of receptor, SOCS3 is highly specific
toward JAKs, rather than other tyrosine kinases. This is high-
lighted by the fact that it displays selectivity even within the
JAK family. Selectivity arises from the fact that SOCS3 interacts
with a motif within the JAK insertion loop. By interacting with this
region, it is able to specifically target JAKs (over other kinases)
and, by targeting the GQM motif, it is able to distinguish JAK1,
JAK2, and TYK2 from JAK3. An evolutionary comparison of
JAK and SOCS sequences is telling in this regard. Only verte-
brates have evolved an expanded JAK system (four JAKs) and
it seems they have also evolved the ability to directly and specif-
ically inhibit three of them. Although theremay be another protein
that functions to inhibit JAK3, it is unlikely to do so via the same
mechanism because JAK3 shows no evolutionary conservation
in the GQM-equivalent region. No other human kinases contain
GQM at this position and therefore SOCS3 would not be ex-
pected to directly inhibit any other kinases in the genome. This
is exemplified by the fact that, in intact cells, JAK1 becomes
unresponsive to SOCS3 if the GQM motif is mutated, even
though it remains tethered next to the kinase on the gp130
receptor. This indicates that JAK3, which lacks GQM, will not
be inhibited by SOCS3 even if they were to be bound to the
same receptor complex.
The SOCS3 binding site on the gp130 receptor, pY757, is also
the binding site of the phosphatase SHP-2, which is involved in
stimulating the Ras/ERK and PI-3K/Akt signaling pathways
(Neel et al., 2003). Mutating this site in mice leads to a Th1
cell-biased immune response, autoimmune arthritis, and the
development of gastric adenoma because of the combined
effect of dysregulating both the JAK-STAT and SHP2-ERK path-
ways (Ernst and Jenkins, 2004). In this context, our JAKGQM-DVP
mutant provides a useful resource because, unlike the
gp130Y757F system, only JAK/STAT signaling (and not SHP2-
ERK signaling) is dysregulated.
Therapeutically, our data have important consequences
because, to our knowledge, SOCS3 is the only biological kinase
inhibitor that acts noncompetitively as regards both ATP and
substrate. Other inhibitors act by competitive mechanisms,
either by blocking the active site directly, for example p27KIP1
(Russo et al., 1996) and RKIP (Yeung et al., 1999), or by disrupt-
ing it allosterically, for example JIP (Barr et al., 2004; Heo et al.,
2004). By virtue of its noncompetitive mechanism, the inhibitory
function of SOCS3 is unaffected by high intracellular ATP
concentration. Structure-guided drug design has historically
targeted the ATP binding site as the most amenable for inhibitor
development. All current JAK inhibitors (Ghoreschi et al., 2009)of ATP and substrate. Lineweaver-Burk curves that intersect on the abscissa
ents.
wo independent experiments) or in the presence of ATP competitive inhibitors
oncentration unlike the IC50 values of ADP and CMP-6. Error bars represent ±
Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc. 247
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enzyme, which has two major drawbacks: (1) ATP in the cell,
which can be as high as 10 mM, competes with inhibitor binding
and leads to reduced efficacy in vivo and (2) the ATP binding site
of tyrosine kinases are all structurally similar and thus specificity
is difficult to achieve. In contrast, a noncompetitive JAK inhibitor
would retain its potency in vivo and may take advantage of the
greater structural variation in regions outside the ATP binding
site to gain greater specificity for JAK over the rest of the kinome
(Cozza et al., 2009). As a specific, noncompetitive JAK inhibitor
that does not bind to the active site of the enzyme, SOCS3 is
the ideal template for the development of a new class of thera-
peutic JAK inhibitors.
Having targeted JAK via both the receptor to which it is
attached and its GQM motif, what then is the molecular mecha-
nism of SOCS3? The noncompetitive nature of inhibition by
SOCS3, and the fact that it does not block phosphate transfer
to water, implies that it does not block or destroy the structure
of the kinase active site. We propose a model in which SOCS3
binding alters the conformation of JAK in such a way that the
distance between the ATP terminal phosphate and the acceptor
tyrosine hydroxyl group, or their relative geometry, is affected.
The GQM motif is located within 8 A˚ of the substrate binding
site of JAK2 and therefore SOCS3 binding may distort its loca-
tion. Even a small shift in their relative positions could dramati-
cally affect phosphate transfer fromATP to the tyrosine hydroxyl,
because these moieties need to be positioned within 3 A˚ to
allow nucleophilic attack within the developing transition state
(Madhusudan et al., 1994). Only the structure of a SOCS-JAK
complex will enable this hypothesis to be examined.
By regulating cytokine signaling, SOCS3 plays a key role in
maintaining the hematopoietic system and controlling the
immune response. Our results reveal the basis for both the effi-
cacy and specificity of SOCS3 action and explain how it is able
to regulate signaling via a particular subset of cytokines. Finally,
our experiments show that unlike all currently available JAK
inhibitors, SOCS3 inhibits JAK via a mechanism in which it is
not affected by high intracellular ATP levels, thereby suggesting
that it is the ideal template upon which to base the development
of a new class of therapeutic JAK inhibitors.EXPERIMENTAL PROCEDURES
Cloning and Expression
All SOCS3 constructs lack the first 21 amino acids and have the PEST motif
(residues 129–163) replaced by a Gly-Serx4 linker, and these modifications
enhance its stability and solubility (Babon et al., 2005, 2006). This parent
construct, SOCS322-225DPEST, was used as a template for all further muta-
genesis and is henceforth referred to as SOCS3. Coexpression and purifica-
tion of SOCS3 with elongins B and C was as previously described (Babon
et al., 2008) Plasmids encoding SOCS2 and SOCS4 were kind gifts of A.
Bullock (SGC, Oxford, UK). The sequence of all constructs is given in Supple-
mental Information.
JAK1, JAK2, JAK3, and TYK2 (kinase domains) were cloned into pFASTBAC
(Invitrogen) and expressed as 6xHIS-tagged proteins. JAK2 mutants were
produced with oligonucleotide-directed PCR mutagenesis. JAK2 was also
expressed as a GST fusion by cloning into pDEST-20 (Invitrogen). All JAK
constructs were expressed and purified as previously described (Lucet et al.,
2006) except that JAK2JH1 used for NMR analysis was expressed in the pres-
ence of 0.4 mM of the JAK inhibitor 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihy-
dro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one (EMD biosciences) to increase248 Immunity 36, 239–250, February 24, 2012 ª2012 Elsevier Inc.yield. Because we were unable to completely displace this inhibitor after puri-
fication, all other assays used JAK expressed in the absence of this inhibitor.
Cloning and Overexpression of JAK1 in JAK1–/– Cell Lines
The JAK1-deficient human fibrosarcoma cell line U4A has been described
previously (McKendry et al., 1991; Guschin et al., 1995) and was maintained
in Dulbecco’s modified Eagle’s medium, supplemented with 10% (v/v) heat-
inactivated fetal calf serum and hygromycin (250 mg/ml). The mutation of
murine JAK1 resulting in the amino acid mutations GQM > DVP for expression
in U4A cells was produced via oligonucleotide-directed PCR mutagenesis.
Wild-type and mutant JAK1 cDNAs were cloned into the puromycin-resistant
plasmid pEF-IRES-P (Hobbs et al., 1998) and transfected into the U4A cell line
with FuGENE HD Transfection Reagent (Roche), according to the manufac-
turer’s instructions. Stable cell lines overexpressing either wild-type JAK1
or the JAK1GQM-DVP mutant were selected with puromycin (2 mg/ml) and
tested for JAK1 expression by protein immunoblot with an antibody to JAK1
(Santa Cruz).
Cytokine Stimulation and Protein Immunoblotting
U4A cells and their derivatives (23 106) were plated overnight in 6-well plates
and pulsed with 400 ng/ml human recombinant IL-6 and 500 ng/ml sIL-6Ra
(R&D Systems, MN) for 15 min. Cells were washed in PBS and lysed for
30 min in 50 ml ice-cold KALB lysis buffer (150 mM NaCl, 50 mM Tris [pH 7.5],
1% [v/v] TritonX-100, 1mMEDTA, 1mMNa3VO4, 1mMNaF, 1mMPMSF) con-
taining protease inhibitors (Complete cocktail tablets; Roche). Lysates were
cleared by centrifugation (13,000 3 g) for 10 min at 4C and supernatants
boiled in 43 reducing sample buffer. A 15 ml sample was separated by SDS-
PAGE, transferred onto polyvinylidene difluoride membranes (Millipore), and
examined for phosphorylated STAT3 (Cell Signaling), total STAT3 (Santa
Cruz), and JAK1 expression by protein immunoblot.
JAK2 Kinase Inhibition Assays by Protein Substrates
1 mg/ml protein substrate was incubated with 50 nM JAK2JH1 at 25
C for
30 min in 20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM DTT, 2 mM ATP, and
4 mM MgCl2 (kinase buffer) and various concentrations of SOCS-elonginBC
complexes. 1 mCi g-[32P]ATP was included to allow visualization of phosphor-
ylation via autoradiography and phosphorimaging. After incubation, the reac-
tions were either boiled and subjected to analysis by SDS-PAGE or terminated
with 50 mM EDTA and spotted onto a nitrocellulose membrane. Membranes
were washed extensively (4 3 200 ml, 15 min) with PBS and subsequently
exposed to a phosphorimager plate (Fuji).
JAK2 Kinase Inhibition Assays via Peptide Substrates
0–2 mM substrate peptide was incubated with 10 nM JAK2JH1 at 25
C for
10–20min in kinase buffer and 1 mCi g-[32P]ATP. After incubation, the reactions
were spotted onto P81 phosphocellulose paper and quenched in 5% H3PO4.
The paper was washed extensively (4 3 200 ml, 15 min) with 5% H3PO4 and
exposed to a phosphorimager plate (Fuji).
Steady-State Kinetics
Michaelis/Menten analysis requires the use of a high enzyme-to-substrate
ratio so that product formation is linearly proportional to time and product inhi-
bition is negligible. Substrate concentration must beRKM to approach satura-
tion and allow accurate determination of Vmax. Therefore, 2 nM JAK2JH1 was
used to phosphorylate 0–5 mM STAT5b peptide in these assays. Inhibitor,
SOCS3-elonginBC, was included at 0–10 mM final concentration. Reactions
were performed in kinase buffer except that both ATP and STAT5b peptide
were titrated independently. 0.1 mg/ml BSA and 1 mCi g-[32P]ATP were added
at 25C. 7.5 and 15min time points were used to ensure that product formation
was linear with time. When ATP was titrated, STAT5b was at 1.6 mM (KM);
when STAT5b was titrated, ATP was at 2 mM (15 3 Km). After incubation,
the reactions were spotted onto P81 phosphocellulose paper (Millipore) and
treated as described in the previous paragraph. Control experiments showed
that retention onto P81 paper was linear to >5 mM peptide.
ATPase Assays
ATPase assays were performed by incubating 0.25 mM JAK2JH1 in kinase
buffer (except that ATP concentration was 0.1 mM) and 1 mCi g-[32P]ATP for
Immunity
Mechanism of Inhibition of Janus Kinase by SOCS330 min at 25C. SOCS3-elonginBC was present in the reaction at 0–10 mM
concentration. Reactions were stopped with 25 mM EDTA, spotted onto
PEI-cellulose TLC plates, and developed in 1 M LiCl, 1 M formic acid for
45 min, air-dried, and exposed to a phosphorimager plate.
NMR
SOFAST-HMQC experiments were recorded at 37C in 20 mM MES, 1 mM
DTT on a Bruker Avance 600 MHz spectrometer equipped with cryoprobe.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at
doi:10.1016/j.immuni.2011.12.015.
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